AXSM · ISSUER CIK 1579428
Axsome Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 2 Axsome Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $12.6M of sales on SEC Form 4.
↗2 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 2 of 2 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$12.6MInsider selling
−$12.6MNet open-market
Sep 3, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 202619:09 | Sep 3, 2026 | AXSM | Chief Operating Officer | S · Sell10b5-1 | $208.65 | −10,000 | 0 | -100% | −$2.1M | ||
| Sep 3, 202619:09 | Sep 3, 2026 | AXSM | Chief Operating Officer | M · Exercise10b5-1 | $12.95 | +10,000 | 10,000 | New | $130K | ||
| Aug 7, 202619:00 | Aug 6, 2026from Aug 5, 2026 | AXSM | Chief Executive Officer, Director, 10% Owner | S · Sell10b5-1 | $212.19 | −49,664 | 7,229 | -87% | −$10.5M | ||
| Aug 7, 202619:00 | Aug 6, 2026from Aug 5, 2026 | AXSM | Chief Executive Officer, Director, 10% Owner | M · Exercise10b5-1 | $4.95 | +49,664 | 11,889 | — | $246K |